Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798314 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
A Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 2
- Study locations
NCT03798314 is a Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03798314, a Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy with monoclonal antibodies, such as pomalidomide and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG Pomalidomide
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798314
The ClinicalTrials.gov registry entry for NCT03798314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Recurrent Nervous System Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03798314 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03798314 about?
NCT03798314 is a clinical study titled "Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma". This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to trea...
What is the current status of trial NCT03798314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-01-30. Estimated completion is 2021-09-15.
What conditions does trial NCT03798314 study?
This clinical trial studies the following conditions: Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL.
What interventions are being tested in trial NCT03798314?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT03798314?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03798314 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Recurrent Nervous System Lymphoma
All registered trials for this condition
Recurrent Primary Vitreoretinal DLBCL
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.